Drug intelligence / Profile preview

GWZ002

Development stage: Unknown
Lead developer: Ginwa Enterprise Group
Administration: Oral

Overview

**GWZ002** is an oral traditional Chinese medicine granule formulation developed for **acute exacerbation of chronic obstructive pulmonary disease**. The formula originated from a long-developed clinical-experience prescription associated with Henan University of Chinese Medicine and was transferred to Ginwa Pharmaceutical Factory for further development and commercialization. It received Chinese clinical-trial authorization in October 2024, and Ginwa subsequently initiated procurement for a Phase II clinical trial in acute exacerbation of chronic obstructive pulmonary disease. ([ginwa.com.cn](https://www.ginwa.com.cn/NewsStd_1176.html))

Beyond the preview

Go deeper on GWZ002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GWZ002.

Explore the full profile